Trial Profile
Efficacy and safety of intravenous immunoglobulin in the maintenance treatment of chronic immune-mediated neuropathies.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 05 Feb 2018
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Chronic inflammatory demyelinating polyradiculoneuropathy
- Focus Therapeutic Use
- 05 Feb 2018 New trial record